Your browser doesn't support javascript.
Type I interferon response and vascular alteration in chilblain-like lesions during the COVID-19 outbreak.
Frumholtz, L; Bouaziz, J-D; Battistella, M; Hadjadj, J; Chocron, R; Bengoufa, D; Le Buanec, H; Barnabei, L; Meynier, S; Schwartz, O; Grzelak, L; Smith, N; Charbit, B; Duffy, D; Yatim, N; Calugareanu, A; Philippe, A; Guerin, C L; Joly, B; Siguret, V; Jaume, L; Bachelez, H; Bagot, M; Rieux-Laucat, F; Maylin, S; Legoff, J; Delaugerre, C; Gendron, N; Smadja, D M; Cassius, C.
  • Frumholtz L; Dermatology Department, AP-HP, Hôpital Saint-Louis, F-75010, Paris, France.
  • Bouaziz JD; Dermatology Department, AP-HP, Hôpital Saint-Louis, F-75010, Paris, France.
  • Battistella M; Université de Paris, Human Immunology Pathophysiology Immunotherapy, INSERM U976, Institut de Recherche Saint-Louis, F-75010, Paris, France.
  • Hadjadj J; Université de Paris, Human Immunology Pathophysiology Immunotherapy, INSERM U976, Institut de Recherche Saint-Louis, F-75010, Paris, France.
  • Chocron R; Pathology Department, AP-HP, Hôpital Saint-Louis, F-75010, Paris, France.
  • Bengoufa D; Université de Paris, Imagine Institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM U1163, F-75015, Paris, France.
  • Le Buanec H; Department of Internal Medicine, National Reference Centre for Rare Systemic Autoimmune Diseases, AP-HP, Hôpital Cochin, F-75014, Paris, France.
  • Barnabei L; Université de Paris, PARCC, INSERM, F-75006, Paris, France.
  • Meynier S; Emergency Department, AP-HP, Georges Pompidou European Hospital, F-75015, Paris, France.
  • Schwartz O; Immunobiology Department, AP-HP, Hôpital Saint-Louis, F-75010, Paris, France.
  • Grzelak L; Université de Paris, Human Immunology Pathophysiology Immunotherapy, INSERM U976, Institut de Recherche Saint-Louis, F-75010, Paris, France.
  • Smith N; Université de Paris, Imagine Institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM U1163, F-75015, Paris, France.
  • Charbit B; Université de Paris, Imagine Institute, Laboratory of Immunogenetics of Pediatric Autoimmune Diseases, INSERM U1163, F-75015, Paris, France.
  • Duffy D; Institut Pasteur, Virus and Immunity Unit, F-75015, Paris, France.
  • Yatim N; Institut Pasteur, Virus and Immunity Unit, F-75015, Paris, France.
  • Calugareanu A; Institut Pasteur, Translational Immunology Lab, F-75015, Paris, France.
  • Philippe A; Institut Pasteur, Cytometry and Biomarkers UTechS, CRT, F-75015, Paris, France.
  • Guerin CL; Institut Pasteur, Translational Immunology Lab, F-75015, Paris, France.
  • Joly B; Institut Pasteur, Cytometry and Biomarkers UTechS, CRT, F-75015, Paris, France.
  • Siguret V; Dermatology Department, AP-HP, Hôpital Saint-Louis, F-75010, Paris, France.
  • Jaume L; Institut Pasteur, Translational Immunology Lab, F-75015, Paris, France.
  • Bachelez H; Dermatology Department, AP-HP, Hôpital Saint-Louis, F-75010, Paris, France.
  • Bagot M; Université de Paris, Human Immunology Pathophysiology Immunotherapy, INSERM U976, Institut de Recherche Saint-Louis, F-75010, Paris, France.
  • Rieux-Laucat F; Institut Pasteur, Cytometry and Biomarkers UTechS, CRT, F-75015, Paris, France.
  • Maylin S; Université de Paris, Innovative Therapies in Haemostasis, INSERM, F-75006, Paris, France.
  • Legoff J; Institut Curie, Cytometry Platform, F-75006, Paris, France.
  • Delaugerre C; Biological Haematology Department, AP-HP, Hôpital Lariboisière, F-75010, Paris, France.
  • Gendron N; Université de Paris, EA3518, Institut de Recherche Saint-Louis, F-75010, Paris, France.
  • Smadja DM; Biological Haematology Department, AP-HP, Hôpital Lariboisière, F-75010, Paris, France.
  • Cassius C; Université de Paris, INSERM UMR S1140, F-75010, Paris, France.
Br J Dermatol ; 185(6): 1176-1185, 2021 12.
Article in English | MEDLINE | ID: covidwho-1455515
ABSTRACT

BACKGROUND:

The outbreak of chilblain-like lesions (CLL) during the COVID-19 pandemic has been reported extensively, potentially related to SARS-CoV-2 infection, yet its underlying pathophysiology is unclear.

OBJECTIVES:

To study skin and blood endothelial and immune system activation in CLL in comparison with healthy controls and seasonal chilblains (SC), defined as cold-induced sporadic chilblains occurring during 2015 and 2019 with exclusion of chilblain lupus.

METHODS:

This observational study was conducted during 9-16 April 2020 at Saint-Louis Hospital, Paris, France. All patients referred with CLL seen during this period of the COVID-19 pandemic were included in this study. We excluded patients with a history of chilblains or chilblain lupus. Fifty patients were included.

RESULTS:

Histological patterns were similar and transcriptomic signatures overlapped in both the CLL and SC groups, with type I interferon polarization and a cytotoxic-natural killer gene signature. CLL were characterized by higher IgA tissue deposition and more significant transcriptomic activation of complement and angiogenesis factors compared with SC. We observed in CLL a systemic immune response associated with IgA antineutrophil cytoplasmic antibodies in 73% of patients, and elevated type I interferon blood signature in comparison with healthy controls. Finally, using blood biomarkers related to endothelial dysfunction and activation, and to angiogenesis or endothelial progenitor cell mobilization, we confirmed endothelial dysfunction in CLL.

CONCLUSIONS:

Our findings support an activation loop in the skin in CLL associated with endothelial alteration and immune infiltration of cytotoxic and type I IFN-polarized cells leading to clinical manifestations.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon Type I / Chilblains / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Br J Dermatol Year: 2021 Document Type: Article Affiliation country: Bjd.20707

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon Type I / Chilblains / COVID-19 Type of study: Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Limits: Humans Country/Region as subject: Europa Language: English Journal: Br J Dermatol Year: 2021 Document Type: Article Affiliation country: Bjd.20707